Discover the latest software purchases and digital transformation initiatives being undertaken by Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 2000 Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.
During our research, we have identified that Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) has purchased the following applications: Cato Secure SD-WAN for SD-WAN in 2017, Microsoft Azure Cloud Services for Application Hosting and Computing Services in 2014, Microsoft 365 for Collaboration in 2015 and the related IT decision-makers and key stakeholders.
Our database provides customer insight and contextual information on which enterprise applications and software systems Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) is running and its propensity to invest more and deepen its relationship with Cato Networks , Microsoft , Mimecast or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.
We have been analyzing Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) revenues, which have grown to $498.0 million in 2021, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.
